drugset
drugset / Trial / NCT00088621

A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia

NCT00088621 ↗

Phase 2 Completed 61 enrolled Sumitomo Pharma America, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia

Timeline

Start
2004-07
Primary completion
2005-10
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 80 mg Oral

Indications

schizophrenia